Literature DB >> 31077000

Breakdown of the Paracellular Tight and Adherens Junctions in the Gut and Blood Brain Barrier and Damage to the Vascular Barrier in Patients with Deficit Schizophrenia.

Michael Maes1,2,3, Sunee Sirivichayakul4, Buranee Kanchanatawan5, Aristo Vodjani6,7,8.   

Abstract

Deficit schizophrenia is characterized by leaky intestinal tight and adherens junctions and bacterial translocation. Here we examine whether (deficit) schizophrenia is accompanied by leaky paracellular, transcellular, and vascular barriers in the gut and blood-brain barriers. We measured IgA responses to occludin, claudin-5, E-cadherin, and β-catenin (paracellular pathway, PARA); talin, actin, vinculin, and epithelial intermediate filament (transcellular pathway, TRANS); and plasmalemma vesicle-associated protein (PLVAP, vascular pathway) in 78 schizophrenia patients and 40 controls. IgA responses to claudin-5, E-cadherin, and β-catenin, the sum of the four PARA proteins, and the ratio PARA/TRANS were significantly higher in deficit schizophrenia patients than in nondeficit schizophrenia patients and controls. A large part of the variance in PHEMN (psychosis, hostility, excitation, mannerism, and negative) symptoms, psychomotor retardation, formal thought disorders, verbal fluency, word list memory, word list recall, and executive functions was explained by the PARA/TRANS ratio coupled with plasma IgA responses to Gram-negative bacteria, IgM to malondialdehyde, CCL-11 (eotaxin), IgA levels of the ratio of noxious to more protective tryptophan catabolites (NOX/PRO TRYCATs), and a plasma immune activation index. Moreover, IgA levels to Gram-negative bacteria were significantly associated with IgA to E-cadherin, β-catenin, and PLVAP, while IgA levels to claudin-5 were significantly predicted by IgA to E-cadherin, NOX/PRO TRYCAT ratio, Gram-negative bacteria, and CCL11. The phenomenology of the deficit syndrome is to a large extent explained by the cumulative effects of lowered natural IgM, breakdown of the paracellular and vascular pathways, increased bacterial translocation, peripheral immune-inflammatory responses, and indices of BBB breakdown.

Entities:  

Mesh:

Year:  2019        PMID: 31077000     DOI: 10.1007/s12640-019-00054-6

Source DB:  PubMed          Journal:  Neurotox Res        ISSN: 1029-8428            Impact factor:   3.911


  85 in total

Review 1.  The blood-brain barrier and its role in inflammation.

Authors:  A A Webb; G D Muir
Journal:  J Vet Intern Med       Date:  2000 Jul-Aug       Impact factor: 3.333

Review 2.  Mechanical aspects of cell shape regulation and signaling.

Authors:  Wolfgang H Goldmann
Journal:  Cell Biol Int       Date:  2002       Impact factor: 3.612

Review 3.  Transmembrane proteins of tight junctions.

Authors:  M S Balda; K Matter
Journal:  Semin Cell Dev Biol       Date:  2000-08       Impact factor: 7.727

4.  Effect of LPS on the permeability of the blood-brain barrier to insulin.

Authors:  H Xaio; W A Banks; M L Niehoff; J E Morley
Journal:  Brain Res       Date:  2001-03-30       Impact factor: 3.252

5.  Anti-S-nitrosocysteine antibodies are a predictive marker for demyelination in experimental autoimmune encephalomyelitis: implications for multiple sclerosis.

Authors:  Anne I Boullerne; Jose J Rodriguez; Tarik Touil; Bruno Brochet; Stephan Schmidt; Nora D Abrous; Michel Le Moal; Jeffrey R Pua; Mark A Jensen; Willy Mayo; Barry G W Arnason; Klaus G Petry
Journal:  J Neurosci       Date:  2002-01-01       Impact factor: 6.167

6.  Adsorptive endocytosis of HIV-1gp120 by blood-brain barrier is enhanced by lipopolysaccharide.

Authors:  W A Banks; A J Kastin; J M Brennan; K L Vallance
Journal:  Exp Neurol       Date:  1999-03       Impact factor: 5.330

7.  Occludin regulates actin cytoskeleton in endothelial cells.

Authors:  H Kuwabara; Y Kokai; T Kojima; R Takakuwa; M Mori; N Sawada
Journal:  Cell Struct Funct       Date:  2001-04       Impact factor: 2.212

8.  Effects of systemic and central nervous system localized inflammation on the contributions of metabolic precursors to the L-kynurenine and quinolinic acid pools in brain.

Authors:  Tomoyuki Kita; Paul F Morrison; Melvyn P Heyes; S P Markey
Journal:  J Neurochem       Date:  2002-07       Impact factor: 5.372

9.  Anti-phosphoinositide auto-antibodies in sera of cancer patients: isotypic and immunochemical characterization.

Authors:  S Faiderbe; J L Chagnaud; M Geffard
Journal:  Cancer Lett       Date:  1992-09-14       Impact factor: 8.679

10.  A rating scale for fibromyalgia and chronic fatigue syndrome (the FibroFatigue scale).

Authors:  Olof Zachrisson; Björn Regland; Marianne Jahreskog; Margareta Kron; Carl G Gottfries
Journal:  J Psychosom Res       Date:  2002-06       Impact factor: 3.006

View more
  14 in total

Review 1.  Increasing Nrf2 Activity as a Treatment Approach in Neuropsychiatry.

Authors:  G Morris; A J Walker; K Walder; M Berk; W Marx; A F Carvalho; M Maes; B K Puri
Journal:  Mol Neurobiol       Date:  2021-01-07       Impact factor: 5.590

2.  Increased Serum Immunoglobulin Responses to Gut Commensal Gram-Negative Bacteria in Unipolar Major Depression and Bipolar Disorder Type 1, Especially When Melancholia Is Present.

Authors:  Denitsa Simeonova; Drozdstoy Stoyanov; Jean-Claude Leunis; Andre F Carvalho; Marta Kubera; Marianna Murdjeva; Michael Maes
Journal:  Neurotox Res       Date:  2019-12-04       Impact factor: 3.911

3.  From "Leaky Gut" to Impaired Glia-Neuron Communication in Depression.

Authors:  Leszek Rudzki; Michael Maes
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  The Role of Brain Microvascular Endothelial Cell and Blood-Brain Barrier Dysfunction in Schizophrenia.

Authors:  Sovannarath Pong; Rakesh Karmacharya; Marianna Sofman; Jeffrey R Bishop; Paulo Lizano
Journal:  Complex Psychiatry       Date:  2020-09-14

5.  Cross-Reactivity and Sequence Homology Between Alpha-Synuclein and Food Products: A Step Further for Parkinson's Disease Synucleinopathy.

Authors:  Aristo Vojdani; Aaron Lerner; Elroy Vojdani
Journal:  Cells       Date:  2021-05-05       Impact factor: 6.600

6.  Chronic fatigue syndrome and fibromyalgia-like symptoms are an integral component of the phenome of schizophrenia: neuro-immune and opioid system correlates.

Authors:  Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Amer Alhaideri; Michael Maes
Journal:  Metab Brain Dis       Date:  2020-09-23       Impact factor: 3.584

7.  High Mobility Group Protein 1 and Dickkopf-Related Protein 1 in Schizophrenia and Treatment-Resistant Schizophrenia: Associations With Interleukin-6, Symptom Domains, and Neurocognitive Impairments.

Authors:  Arafat Hussein Al-Dujaili; Rana Fadhil Mousa; Hussein Kadhem Al-Hakeim; Michael Maes
Journal:  Schizophr Bull       Date:  2021-03-16       Impact factor: 9.306

8.  Increased Levels of Plasma Tumor Necrosis Factor-α Mediate Schizophrenia Symptom Dimensions and Neurocognitive Impairments and Are Inversely Associated with Natural IgM Directed to Malondialdehyde and Paraoxonase 1 Activity.

Authors:  Michael Maes; Sunee Sirivichayakul; Andressa Keiko Matsumoto; Annabel Maes; Ana Paula Michelin; Laura de Oliveira Semeão; João Victor de Lima Pedrão; Estefania G Moreira; Decio S Barbosa; Michel Geffard; Andre F Carvalho; Buranee Kanchanatawan
Journal:  Mol Neurobiol       Date:  2020-02-10       Impact factor: 5.590

9.  Thymoma Associated Myasthenia Gravis (TAMG): Differential Expression of Functional Pathways in Relation to MG Status in Different Thymoma Histotypes.

Authors:  Yosuke Yamada; Cleo-Aron Weis; Julian Thelen; Carsten Sticht; Berthold Schalke; Philipp Ströbel; Alexander Marx
Journal:  Front Immunol       Date:  2020-04-16       Impact factor: 7.561

Review 10.  The blood-brain and gut-vascular barriers: from the perspective of claudins.

Authors:  Anna Agata Scalise; Nikolaos Kakogiannos; Federica Zanardi; Fabio Iannelli; Monica Giannotta
Journal:  Tissue Barriers       Date:  2021-06-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.